Idarubicin (DB01177): A Comprehensive Clinical and Pharmacological Monograph

Section 1: Drug Identification and Physicochemical Properties

1.1 Overview and Classification

Idarubicin is a potent, semi-synthetic antineoplastic agent belonging to the anthracycline class of antibiotics.[1] It is classified as a small molecule and a derivative of a natural product, primarily utilized in the chemotherapeutic treatment of specific hematological malignancies.[3] As a member of the antitumor antibiotic family, Idarubicin is a cornerstone of induction therapy for certain types of leukemia, distinguished from its parent compounds by its high lipophilicity and enhanced potency.[2]

1.2 Nomenclature and Identifiers

Idarubicin is the International Nonproprietary Name (INN) for the active substance, which is also available for clinical use as Idarubicin Hydrochloride.[1] The drug is known by several synonyms, with the most chemically descriptive being 4-demethoxydaunorubicin, which highlights its structural relationship to the parent compound, daunorubicin.[1] Other historical and research identifiers include IMI-30 and NSC-256439.[1] A comprehensive list of its key identifiers is provided in Table 1.1.

1.3 Chemical and Physical Characteristics

Idarubicin has the molecular formula C26​H27​NO9​ and a molecular weight of approximately 497.49 g/mol.[8] It exists as a solid that is formulated for clinical use as a sterile, red-orange, isotonic parenteral solution.[4] The increased lipophilicity imparted by the removal of the methoxy group is a defining physicochemical characteristic that profoundly influences its pharmacological behavior.[2] For storage, the compound requires protection from light and is kept in dry, sealed conditions at 2-8°C for short-term stability or -20°C for long-term storage.[4]

The synonym "4-demethoxydaunorubicin" provides a fundamental clue to understanding Idarubicin's distinct clinical profile. This name explicitly describes the single, critical structural modification relative to its parent compound: the absence of a methoxy group at the C-4 position of the anthracycline's aglycone ring.[2] This seemingly minor chemical change precipitates a cascade of significant pharmacological consequences. It markedly increases the molecule's fat solubility (lipophilicity), which directly enhances its ability to diffuse across cell membranes, leading to greater cellular uptake.[2] This property is also responsible for its ability to cross the blood-brain barrier and its potential for oral bioavailability, features that distinguish it from less lipophilic anthracyclines like daunorubicin and doxorubicin.[5] Thus, this structural modification is the root cause of its altered pharmacokinetics, heightened potency, and unique clinical characteristics.

Table 1.1: Key Identifiers and Physicochemical Properties of Idarubicin

Identifier Type	Value	Source(s)
DrugBank ID	DB01177	1
CAS Number	58957-92-9 (free base)	1
CAS Number (HCl)	57852-57-0	1
ATC Code	L01DB06	2
Molecular Formula	C26​H27​NO9​	1
Molecular Weight	497.49 g/mol	4
IUPAC Name	(7S,9S)-9-acetyl-7-oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione	1
InChIKey	XDXDZDZNSLXDNA-TZNDIEGXSA-N	1

Section 2: Pharmacology and Mechanism of Action

2.1 Pharmacodynamic Classification

Idarubicin is an antineoplastic agent of the anthracycline class, with its primary pharmacological action being the inhibition of DNA Topoisomerase II.[1] This mechanism places it in the category of cytotoxic drugs that interfere with fundamental processes of DNA replication and repair. Reflecting its origins, it is also classified as an antineoplastic antibiotic, though it lacks the specificity for microorganisms required for anti-infective therapy.[1]

2.2 Molecular Mechanism of Cytotoxicity

The cytotoxic activity of Idarubicin is multifaceted, arising from its ability to disrupt several critical cellular processes, primarily centered on DNA.

Primary Mechanism: Topoisomerase II Inhibition

The principal mechanism of action involves the disruption of topoisomerase II, an essential enzyme that modulates DNA topology by creating and resealing transient double-strand breaks, thereby allowing for processes like replication and transcription to proceed without entanglement.2 Idarubicin's action is a two-step process. First, the planar tetracyclic ring of the molecule inserts itself, or intercalates, between the base pairs of the DNA double helix, forming a stable drug-DNA complex.11 This complex then acts as a physical obstacle that traps the topoisomerase II enzyme after it has cleaved the DNA strands. By stabilizing this "cleavable complex," Idarubicin prevents the subsequent re-ligation of the DNA strands.13 The accumulation of these permanent, lethal double-strand DNA breaks triggers cellular apoptosis pathways, leading to cell death.11

Secondary Mechanisms

In addition to its primary effect on topoisomerase II, Idarubicin exerts its cytotoxicity through several other mechanisms:

• Free Radical Generation: Common to all anthracyclines, Idarubicin can chelate iron. This drug-iron complex is capable of undergoing redox cycling, which generates highly reactive oxygen species (free radicals).[1] These free radicals cause widespread oxidative damage to DNA, proteins, and lipid membranes, contributing to the drug's overall cytotoxicity and, importantly, its cardiotoxic side effects.[11]
• Chromatin Disruption: Idarubicin has been shown to induce the eviction of histones from chromatin.[2] This action fundamentally disrupts the nucleosomal structure of DNA, altering genome organization and interfering with the regulation of gene expression.
• Inhibition of Nucleic Acid Synthesis: The drug may also directly inhibit the activity of DNA and RNA polymerases, further impeding the cell's ability to replicate and transcribe its genetic material.[1]

2.3 Cellular and In Vitro Effects

The pleiotropic mechanisms of Idarubicin lead to complex effects at the cellular level. It is described as cell cycle phase-specific, capable of arresting cell growth in the G1 and G2 phases.[11] However, because its fundamental DNA-damaging properties can affect cells at any point in their lifecycle, the anthracycline class is also broadly considered cell cycle-nonspecific.[1] This apparent discrepancy likely reflects that while it may induce arrest at specific checkpoints, its ultimate lethality is not confined to a single phase. Reflecting its antibiotic heritage, Idarubicin has also demonstrated some in vitro inhibitory activity against certain gram-positive bacteria and yeasts.[9]

The drug's mechanism of action directly foreshadows its clinical profile of high potency and severe toxicity. The inhibition of topoisomerase II, which is highly effective against the rapidly dividing cells characteristic of leukemia, is the same mechanism responsible for the profound damage to rapidly dividing hematopoietic precursor cells in the bone marrow, leading to myelosuppression.[11] Furthermore, this DNA-damaging action underlies its mutagenic potential and the associated risk of therapy-related secondary cancers.[11] The secondary mechanism involving iron chelation and free radical generation provides a direct mechanistic link to the drug's most feared dose-limiting toxicity: anthracycline-induced cardiotoxicity.[11]

Section 3: Pharmacokinetic Profile

3.1 Absorption and Bioavailability

Idarubicin exhibits pharmacokinetic properties that distinguish it from other anthracyclines, largely driven by its high lipophilicity. While the standard route for treating acute myeloid leukemia (AML) is intravenous (IV) administration, which ensures 100% bioavailability, Idarubicin is also notable for its potential for oral absorption.[5] When administered orally, absorption is rapid but can be erratic, with an estimated average bioavailability of 35%.[5] Preliminary evidence suggests that co-administration with food may increase the amount of drug absorbed.[12]

3.2 Distribution

The high lipophilicity of Idarubicin results in extensive distribution throughout the body.[2] This is quantitatively reflected in its very large volume of distribution (

Vd), estimated at 1700-1800 L/m², which indicates that the majority of the drug resides in tissues rather than in the plasma.[11] Idarubicin is highly bound to plasma proteins (approximately 97%), a property shared by its active metabolite.[2] A key consequence of its lipophilic nature is its ability to penetrate the central nervous system by crossing the blood-brain barrier.[5]

3.3 Metabolism

Idarubicin undergoes rapid and extensive metabolism, primarily in the liver. The principal metabolic pathway is the reduction of the C-13 keto group by aldoketo reductases to form its main active metabolite, idarubicinol.[5] The clinical pharmacology of Idarubicin is inseparable from that of idarubicinol, as this metabolite is a major contributor to the drug's overall therapeutic and toxic effects. Idarubicinol is as potent as the parent compound and exhibits a much longer plasma half-life, resulting in sustained exposure.[11] The area under the plasma concentration-time curve (AUC) for idarubicinol is approximately 5.1 times higher than that of the parent drug following IV administration, indicating greater systemic exposure to the metabolite over time.[12] The drug also undergoes extensive enterohepatic recycling, which contributes to the prolonged plasma levels of idarubicinol.[11]

3.4 Elimination

Elimination of Idarubicin and its metabolites occurs predominantly through biliary excretion into the feces, with a smaller fraction eliminated via renal excretion in the urine.[5] The elimination kinetics of the parent drug and its active metabolite differ dramatically, a critical factor in the drug's clinical behavior.

The pharmacokinetic profile is dominated by the formation and slow elimination of the potent, long-acting metabolite, idarubicinol. While the initial administration of Idarubicin provides an immediate cytotoxic effect, its rapid conversion to idarubicinol means the patient's body remains exposed to a highly active antineoplastic agent for a prolonged period. Plasma levels of idarubicinol are sustained for over a week, long after the parent drug is cleared.[15] This sustained exposure provides a clear pharmacological basis for the timing of the drug's primary dose-limiting toxicity. The nadir of myelosuppression, or the point of lowest blood cell counts, typically occurs 10 to 14 days after administration—a timeframe that aligns perfectly with the persistent cytotoxic pressure exerted by idarubicinol, not the parent drug.[18] This understanding reframes the clinical challenge as one of managing not just a single dose of Idarubicin, but the accumulation and prolonged effects of its powerful metabolite.

Table 3.1: Comparative Pharmacokinetic Parameters of Idarubicin and Idarubicinol

Parameter	Idarubicin (Parent Drug)	Idarubicinol (Active Metabolite)	Source(s)
Terminal Half-Life	11–25 hours	41–69 hours	2
Plasma Protein Binding	~97%	~94%	11
Relative Potency	Baseline	As potent as parent drug	11
Relative Plasma AUC	Baseline	~5 times higher than parent drug	12

Section 4: Clinical Efficacy and Therapeutic Applications

4.1 Approved Indications

The primary U.S. Food and Drug Administration (FDA)-approved indication for Idarubicin is for the treatment of Acute Myeloid Leukemia (AML) in adults.[2] It is used as a first-line agent in combination with other approved antileukemic drugs, most notably cytarabine.[2] This indication covers all subtypes of the French-American-British (FAB) classification system, from M1 through M7.[10] The combination of an anthracycline with cytarabine for 7 days, known as the "7+3" regimen, has been the standard of care for AML induction for decades.[21]

4.2 Other Clinical Uses and Investigated Applications

Beyond its primary role in AML, Idarubicin has been used or investigated for other hematologic malignancies and solid tumors:

• Other Leukemias: It is used in the treatment of Acute Lymphoblastic Leukemia (ALL) and in the management of Chronic Myelogenous Leukemia (CML) that has progressed to a blast crisis phase.[2]
• Solid Tumors and Lymphomas: Preclinical and some clinical studies have shown Idarubicin to have activity against breast cancer and various lymphomas.[1]
• Myeloproliferative Neoplasms (MPN): The drug is under investigation in Phase 2 clinical trials for the treatment of MPN.[23]
• Other Conditions: It is also listed as a treatment for Leukocytoclastic Vasculitis.[8]

4.3 Clinical Trial Highlights and Efficacy in AML

In its primary indication, Idarubicin has consistently demonstrated high efficacy. When used in combination with cytarabine for induction therapy, it achieves complete remission (CR) rates ranging from approximately 60% to over 80%, depending on the specific trial design, patient population, and comparator agent.[21]

The clinical utility of Idarubicin is highly concentrated in the treatment of acute leukemias. This specific application is a direct consequence of its mechanism and toxicity profile. The therapeutic goal in AML is the rapid and profound cytoreduction of the leukemic clone within the bone marrow. This objective necessitates a treatment that is potent enough to achieve marrow aplasia, making the severe myelosuppression caused by Idarubicin not just a side effect, but an accepted, on-target component of its therapeutic action. In contrast, for most solid tumors, treatment strategies aim to shrink the tumor while preserving bone marrow function to the greatest extent possible, allowing for repeated cycles of therapy over a longer duration. The severe and prolonged myelosuppression induced by Idarubicin and its long-acting metabolite makes it a less favorable agent for many solid tumor regimens compared to other anthracyclines like doxorubicin, which has a broader spectrum of approved uses in solid tumors.[1] This divergence explains the clinical positioning of these agents: Idarubicin and its close relative daunorubicin are primarily "leukemia drugs," while doxorubicin is a workhorse for "solid tumor" oncology, despite their shared core mechanism.

Section 5: Dosage, Administration, and Clinical Management

5.1 Recommended Dosing Regimens for AML

The dosing of Idarubicin is based on body surface area (m2) and the specific phase of treatment.

• Induction Therapy (Adults): The standard recommended dose is 12 mg/m² administered daily for three consecutive days.[16] This is typically part of a combination regimen with cytarabine.[16]
• Consolidation Therapy: Dosing schedules for consolidation can vary. Regimens cited in clinical trials include 10-12 mg/m² per day for two days or a single dose of 15 mg/m².[25] The benefit of intensive consolidation or maintenance therapy with Idarubicin is not definitively established and must be weighed against the risk of cumulative toxicity.[15]
• Pediatric Dosing: While safety and efficacy have not been formally established in the US for patients under 18, a dose of 10 mg/m² IV daily for three days has been recommended in some pediatric protocols.[16]

5.2 Administration Protocol

Strict adherence to administration protocol is critical to minimize the risk of severe local toxicity.

• Route of Administration: Idarubicin is for Intravenous (IV) administration ONLY. It must never be administered via the intramuscular (IM) or subcutaneous (SC) routes, as this carries a high risk of causing severe local tissue damage and necrosis.[10]
• Infusion Technique: The drug should be injected slowly over a 10- to 15-minute period into the side port or tubing of a freely flowing IV infusion of a compatible solution, such as normal saline. The patency of the IV line must be confirmed before and during administration.[16] This slow infusion technique helps to reduce the incidence of local reactions like phlebitis and erythematous streaking along the vein.[5]
• Extravasation Management: Extravasation, the accidental leakage of the vesicant drug into surrounding subcutaneous tissue, is a medical emergency. If signs or symptoms such as pain, burning, swelling, or redness occur at the injection site, the infusion must be stopped immediately and restarted in a different vein. Management of extravasation requires immediate expert consultation and may involve the use of dexrazoxane as an antidote to prevent or reduce tissue injury.[18]

5.3 Dose Adjustments and Special Populations

The standard dose of Idarubicin must be adjusted in patients with organ dysfunction to avoid excessive toxicity.

• Hepatic Impairment: Dose reduction is mandatory. While specific guidelines vary, treatment is often contraindicated if the serum bilirubin level exceeds 5 mg/dL. A 50% dose reduction is generally recommended for patients with bilirubin levels between 1.2 and 2.0 mg/dL.[15]
• Renal Impairment: Dose reduction is also recommended for patients with impaired renal function. Specific guidelines suggest reducing the dose by 25% for a creatinine clearance (CrCl) less than 50 mL/min and by 50% for a CrCl less than 10 mL/min.[26]
• Severe Mucositis: If a patient develops severe mucositis following the first course of induction, the second course should be delayed until this toxicity has resolved. A dose reduction of 25% is recommended for the subsequent course.[16]
• Geriatric Patients: Patients over the age of 60 are at a higher risk for developing cardiotoxicity and may experience adverse events more frequently than younger patients.[11]

5.4 Clinical and Laboratory Monitoring

The use of Idarubicin requires a comprehensive monitoring strategy to manage its potent effects and severe toxicities.

• Supervision: Treatment must be administered under the direct supervision of a physician experienced in leukemia chemotherapy and in a facility with adequate laboratory and supportive resources to manage life-threatening complications like severe infection or hemorrhage.[15]
• Hematologic Monitoring: Frequent monitoring of complete blood counts (CBC) is essential to track the depth and duration of the expected severe myelosuppression.[15]
• Cardiac Function: A baseline assessment of cardiac function, typically via an echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan to measure the left ventricular ejection fraction (LVEF), is required before initiating therapy. Cardiac function must be monitored throughout treatment, especially in patients with pre-existing risk factors or those approaching cumulative dose limits.[16]
• Organ Function: Liver function (serum bilirubin) and renal function (serum creatinine) must be evaluated at baseline and periodically during treatment to guide dosing.[16]
• Tumor Lysis Syndrome: Serum electrolytes and uric acid should be monitored, particularly in patients with a high tumor burden, to detect and manage tumor lysis syndrome (TLS).[11]

The entire framework for dosing, administration, and monitoring Idarubicin constitutes a proactive clinical risk management strategy. This protocol is not arbitrary; it is built directly upon the foundation of the drug's known pharmacology and severe, predictable toxicities. The slow IV infusion is designed to mitigate the risk of local tissue damage from this potent vesicant.[18] The vigilant monitoring of the heart, bone marrow, liver, and kidneys represents a surveillance program for the organs most susceptible to damage.[16] The built-in dose adjustment rules for organ dysfunction or excessive toxicity act as a crucial feedback loop, acknowledging that a "standard" dose may be an overdose for a patient with compromised physiology.[16] Finally, the requirement for administration in a specialized setting ensures that when the inevitable and severe complications of therapy arise, the expertise and resources are immediately available to manage them.[15] This demonstrates that the clinical practice of using Idarubicin is an inseparable and direct response to its potent and dangerous pharmacological profile.

Table 5.1: Idarubicin Dose Adjustment Guidelines

Condition	Parameter	Recommended Dose Adjustment	Source(s)
Hepatic Impairment	Serum Bilirubin 2.6–5.0 mg/dL	Reduce dose by 50%	26
	Serum Bilirubin >5.0 mg/dL	Avoid use / Contraindicated	26
Renal Impairment	CrCl 10–50 mL/min	Reduce dose by 25%	26
	CrCl <10 mL/min	Reduce dose by 50%	26
Toxicity-Related	Severe Mucositis after 1st Course	Delay 2nd course until recovery and reduce dose by 25%	16

Section 6: Safety Profile and Adverse Drug Reactions

6.1 U.S. Boxed Warnings

The FDA label for Idarubicin includes several boxed warnings, the highest level of warning, to underscore its most severe and potentially fatal risks.[15]

• Myelosuppression: Idarubicin is a potent bone marrow suppressant. Severe myelosuppression, the most common acute dose-limiting toxicity, will occur in all patients receiving a therapeutic dose. This can lead to life-threatening infections and/or bleeding.[15]
• Cardiotoxicity: The drug can cause myocardial toxicity, manifesting as potentially fatal congestive heart failure (CHF), arrhythmias, or cardiomyopathy. This toxicity can be acute or delayed, occurring months to years after treatment completion. The risk is increased by prior anthracycline therapy or pre-existing cardiac disease.[5]
• Administration and Extravasation: Idarubicin is for intravenous administration only. Extravasation during infusion can lead to severe local tissue damage, including blistering, cellulitis, and necrosis.[16]
• Administration by Experienced Physicians: Treatment should only be conducted under the supervision of a physician experienced in leukemia chemotherapy and in facilities equipped to manage its severe toxicities.[15]

6.2 Common and Frequent Adverse Effects (>10% incidence)

The adverse effect profile of Idarubicin is extensive, with many toxicities being a direct consequence of its potent cytotoxic action.

• Hematologic: Severe myelosuppression is an expected outcome, manifesting as severe neutropenia (with a nadir at 10-14 days), thrombocytopenia, and anemia.[15]
• Infection: As a direct result of neutropenia, infection is the most commonly reported adverse reaction, occurring in up to 95% of patients in clinical trials.[15]
• Gastrointestinal: Nausea and vomiting are very common (reported incidences range from 30% to 82%). Mucositis (inflammation and ulceration of the mouth and throat), abdominal cramps, and diarrhea are also frequent, affecting a majority of patients.[15]
• Dermatologic: Alopecia (hair loss) is a very common and distressing side effect, affecting up to 77% of patients. Rashes and other skin changes are also frequently observed.[15]
• Hemorrhage: Bleeding events, exacerbated by severe thrombocytopenia, are common, with reported rates as high as 63%.[15]
• General Effects: Fever, chills, headache, and loss of appetite are frequently reported.[29] A benign red-orange discoloration of the urine is an expected and harmless effect for 1-2 days following administration due to the color of the drug.[16]

6.3 Serious and Rare Adverse Effects

• Tumor Lysis Syndrome (TLS): The rapid destruction of a large number of leukemic cells can release intracellular contents into the bloodstream, leading to hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia. This can precipitate acute renal failure and is a medical emergency.[11]
• Secondary Malignancy: Due to its mutagenic properties, Idarubicin can cause therapy-related secondary cancers, most commonly acute myeloid leukemia or myelodysplastic syndrome (t-AML/MDS). These malignancies can develop with a latency period of 1 to 3 years after treatment.[11]
• Radiation Recall: Idarubicin can reactivate or enhance inflammatory reactions in tissues previously exposed to radiation therapy. This "recall" phenomenon can occur weeks to months after the completion of radiation.[5]
• Severe Gastrointestinal Events: Although rare, severe enterocolitis with intestinal perforation has been reported.[15]
• Anaphylaxis: Life-threatening systemic allergic reactions can occur but are rare.[31]

6.4 Reproductive and Developmental Toxicity

• Fertility: Idarubicin is known to be toxic to the reproductive organs and can impair fertility in both men and women. It can cause chromosomal damage to human spermatozoa. Patients of reproductive potential should be counseled on fertility preservation options prior to starting treatment.[11]
• Pregnancy and Contraception: The drug is genotoxic and has demonstrated embryotoxicity and teratogenicity in animal studies.[11] It is not recommended for use during pregnancy. Due to the risk of harm to a developing fetus, effective contraception is mandatory for female patients during treatment and for at least 6.5 months after the final dose. Male patients with partners of childbearing potential must use effective contraception during treatment and for at least 3.5 months after the final dose.[5]
• Breastfeeding: It is not known if Idarubicin is excreted into human milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding should be discontinued during treatment and for at least 14 days after the last dose.[5]

The safety profile of Idarubicin is a direct manifestation of its high, indiscriminate potency. The toxicities are not merely side effects but are mechanistically intertwined with its therapeutic action, creating a narrow and challenging therapeutic window. The very mechanism that kills leukemic cells—DNA damage and inhibition of replication—is the same one that destroys healthy, rapidly dividing hematopoietic stem cells, making severe myelosuppression an unavoidable consequence of an effective dose.[15] The risk of cardiotoxicity is cumulative, not just for Idarubicin itself, but across all anthracyclines a patient may have received previously, creating a "pharmacological memory" that limits future treatment options.[5] The risk of secondary leukemia is the ultimate double-edged sword, where the treatment for one cancer can cause another, a direct result of the drug's mutagenic mechanism.[11] This transforms the risk-benefit calculation from a short-term consideration of achieving remission to a long-term, lifelong assessment of risk.

Section 7: Significant Drug and Disease State Interactions

The safe use of Idarubicin requires careful consideration of its numerous potential interactions with other drugs and pre-existing patient conditions. There are over 500 drugs known to interact with Idarubicin.[35]

7.1 Pharmacodynamic Interactions (Additive Toxicity)

These interactions occur when co-administered drugs have similar toxic effects, leading to an amplification of risk.

• Other Cardiotoxic Agents: The risk of cardiotoxicity is significantly increased when Idarubicin is used concomitantly with other cardiotoxic agents. This includes other anthracyclines (doxorubicin, daunorubicin), anthracenediones (mitoxantrone), targeted therapies (trastuzumab, bevacizumab), and other chemotherapies (cyclophosphamide, paclitaxel). Such combinations require extremely close cardiac monitoring.[5]
• Other Myelosuppressive Agents: Co-administration with other drugs that suppress bone marrow function (e.g., most other cytotoxic chemotherapies, clozapine) will enhance the depth and duration of myelosuppression, increasing the risk of severe neutropenia, infection, and bleeding.[27]
• Anticoagulants and Antiplatelet Agents: The risk of hemorrhage is increased when Idarubicin is combined with anticoagulants (e.g., acenocoumarol) or antiplatelet drugs (e.g., aspirin, abciximab), as the drug-induced thrombocytopenia is compounded by the inhibition of the coagulation cascade or platelet function.[14]

7.2 Pharmacodynamic Interactions (Altered Efficacy)

• Vaccines: As a potent immunosuppressant, Idarubicin can blunt the immune response to vaccines, rendering them less effective. More critically, the administration of live or live-attenuated vaccines (e.g., adenovirus, MMR, varicella) to a severely immunocompromised patient can result in a disseminated, life-threatening infection. Live vaccines are contraindicated during and for a period following Idarubicin therapy.[14]

7.3 Pharmacokinetic Interactions

• Metabolic Pathway Interactions: Idarubicin's metabolism can be altered by various drugs. For instance, abatacept may increase its metabolism (potentially reducing efficacy), while common drugs like acetaminophen and specific agents like abiraterone may decrease its metabolism (potentially increasing toxicity).[14]
• P-glycoprotein (P-gp) Transporter Interactions: Idarubicin is a substrate of the P-gp efflux pump. Co-administration with P-gp inhibitors (e.g., erdafitinib, lasmiditan) can increase plasma concentrations of Idarubicin and its associated toxicities. Such combinations should generally be avoided.[26]

7.4 Disease State Interactions and Contraindications

A patient's underlying health status profoundly influences the safety of Idarubicin.

• Pre-existing Cardiac Disease: A history of severe cardiac disease, recent myocardial infarction, severe arrhythmias, or prior treatment with maximum cumulative doses of other anthracyclines are strong relative or absolute contraindications to Idarubicin use.[30]
• Severe Myelosuppression: The drug should not be used in patients with pre-existing, marked bone marrow suppression from prior therapies unless the potential benefit unequivocally warrants the risk.[15]
• Hepatic and Renal Impairment: Idarubicin is contraindicated in patients with severe hepatic or renal impairment. Dose adjustments are essential for those with mild-to-moderate dysfunction.[30]
• Uncontrolled Infections: Active, systemic infections must be controlled before initiating Idarubicin therapy, as the subsequent profound neutropenia would render the patient unable to fight the infection.[27]

The interaction profile highlights that safe management extends beyond the drug itself to the patient as a whole. The concept of cumulative cardiotoxicity means that a patient's entire treatment history functions as a source of drug interaction, creating a temporal dimension to risk assessment.[5] The disease state interactions are not novel toxicities, but rather pre-existing conditions that lower the patient's threshold to the drug's known adverse effects.[35] Therefore, the safe administration of Idarubicin demands a comprehensive evaluation of the patient's past medical history, prior cancer treatments, and all concomitant medications to construct a complete risk profile before the first dose is considered.

Section 8: Comparative Analysis: Idarubicin vs. Daunorubicin and Doxorubicin

The choice of anthracycline for AML induction has been a subject of extensive clinical research for decades. The debate has primarily centered on the relative efficacy and toxicity of Idarubicin versus its predecessors, Daunorubicin and Doxorubicin.

8.1 Potency and Structural Basis for Differences

Idarubicin's key structural difference is the lack of a methoxy group at the C-4 position compared to daunorubicin.[2] This modification increases its lipophilicity, which enhances cellular uptake and contributes to its greater potency. Idarubicin is estimated to be 5 to 6 times more potent than daunorubicin.[5]

8.2 Comparative Efficacy in AML: An Evolving Narrative

The understanding of Idarubicin's relative efficacy has evolved significantly over time.

• Initial Paradigm (vs. Standard-Dose Daunorubicin): Early randomized trials conducted in the 1990s established the superiority of Idarubicin. These studies compared Idarubicin (at 12 mg/m²/day for 3 days) against the then-standard dose of Daunorubicin (45 mg/m²/day for 3 days). The results consistently showed significantly higher complete remission (CR) rates in the Idarubicin arm, with one landmark study reporting a CR rate of 71% for Idarubicin versus 58% for Daunorubicin (p=.03).[22] This led to Idarubicin becoming the preferred anthracycline for AML induction for many years.
• The Dose-Escalation Era (vs. High-Dose Daunorubicin): This paradigm was challenged by subsequent trials that investigated dose-escalated Daunorubicin. When Idarubicin (12 mg/m²) was compared to high-dose Daunorubicin (90 mg/m²), the efficacy gap closed. Multiple large, randomized trials found no significant differences in CR rates, overall survival (OS), or event-free survival (EFS) between the two arms in the general population of younger adults with AML.[37] This suggests that the initial superiority of Idarubicin may have been a result of comparing it to a biologically suboptimal dose of Daunorubicin.[37]
• The Era of Personalized Medicine (The FLT3-ITD Insight): The most recent and sophisticated development in this comparison comes from subgroup analysis of modern trials. A pivotal phase III study identified a significant interaction between the treatment arm and the presence of a FLT3 internal tandem duplication (ITD) mutation, a marker of high-risk AML. In this specific patient subgroup, the high-dose Daunorubicin regimen was associated with significantly better outcomes than the Idarubicin regimen (median OS: not reached vs. 15.5 months, respectively; p=.030).[37]

This evolution in understanding signifies a major shift in clinical practice. The question is no longer a simple one of which drug is globally superior. Instead, it has become a nuanced decision that must account for dose and, most importantly, the specific molecular characteristics of the patient's leukemia. The discovery of differential efficacy in the FLT3-ITD population marks a critical step toward personalized medicine in AML induction therapy.

8.3 Comparative Toxicity and Clinical Application

• Toxicity: Direct comparisons have revealed differences in toxicity profiles. One study comparing Idarubicin to Doxorubicin found that severe oral mucositis was significantly more common with Doxorubicin, while invasive fungal infections were more frequent with Idarubicin.[21] During consolidation therapy, Idarubicin has been shown to cause more profound myelosuppression than standard-dose Daunorubicin, further supporting the hypothesis of non-equivalent dosing in early trials.[37]
• Clinical Roles: The clinical applications of these agents have diverged. Idarubicin and Daunorubicin are used almost exclusively for the treatment of leukemias. In contrast, Doxorubicin has a much broader spectrum of activity and is a key agent in the treatment of numerous solid tumors, including breast, bladder, and lung cancer, as well as lymphomas.[1]
• Pharmacoeconomics: In at least one analysis, a Doxorubicin-based regimen for AML was found to have a lower overall cost than an Idarubicin-based regimen while providing comparable efficacy, presenting a potential cost-saving alternative in certain healthcare systems.[21]

Table 8.1: Head-to-Head Comparison of Anthracyclines in AML Induction Therapy

Comparison	Key Outcome	Result / Finding	Source(s)
Idarubicin (12 mg/m²) vs. Daunorubicin (45 mg/m²)	Complete Remission (CR) Rate	Idarubicin significantly superior (71% vs. 58%, p=.03)	25
Idarubicin (12 mg/m²) vs. Daunorubicin (90 mg/m²)	CR Rate, Overall Survival (OS)	No significant difference; regimens are equivalent in overall population	37
Idarubicin (12 mg/m²) vs. Daunorubicin (90 mg/m²) in FLT3-ITD+ AML	Overall Survival (OS)	High-dose Daunorubicin significantly superior (median OS not reached vs. 15.5 months, p=.030)	37
Idarubicin (12 mg/m²) vs. Doxorubicin (45 mg/m²)	CR Rate	No significant difference (49.2% vs. 52.5%, p=.6)	21
Idarubicin (12 mg/m²) vs. Doxorubicin (45 mg/m²)	Grade 3/4 Oral Mucositis	Significantly higher with Doxorubicin (70.8% vs. 37%, p=.0001)	21

Section 9: Regulatory Status and Commercial Landscape

9.1 FDA Approval History

• Orphan Drug Designation: On July 25, 1988, the FDA granted orphan drug designation to Idarubicin HCl for the treatment of acute myelogenous leukemia (AML), also referred to as acute nonlymphocytic leukemia.[20]
• Marketing Approval: The New Drug Application for Idarubicin (trade name: Idamycin) was approved by the FDA on September 27, 1990.[20]
• Generic Availability: The period of market exclusivity for the orphan drug indication ended on September 27, 1997.[20] This paved the way for generic competition, and multiple manufacturers have since received FDA approval for generic idarubicin hydrochloride injection, with the first approvals dating to the early 2000s.[40]

9.2 Global Brand Names and Formulations

Idarubicin is marketed under various brand names worldwide.

• United States: The primary brand names are Idamycin® and Idamycin PFS® (Preservative-Free Solution), marketed by Pfizer.[7]
• United Kingdom and Europe: It is commonly distributed under the trade name Zavedos®.[2]
• India: The brand name Zavedos® is also available in India, marketed by Pfizer and its affiliates.[42]
• Formulations: The standard clinical formulation is an injectable solution at a concentration of 1 mg/mL, supplied in single-use vials containing 5 mg, 10 mg, or 20 mg of the drug.[10] While oral capsules have been used in clinical studies, the intravenous formulation is the standard for AML treatment.[12]

Section 10: Concluding Remarks and Expert Insights

Idarubicin is a highly potent, second-generation anthracycline whose clinical identity is defined by a critical structural modification—the removal of a methoxy group—that enhances its lipophilicity and cellular penetration. This results in significant efficacy in the treatment of acute leukemias, an efficacy that is inextricably linked to a profile of severe, predictable, and life-threatening toxicities. The drug's pharmacokinetic behavior, characterized by its rapid conversion to an equally potent and much longer-acting metabolite, idarubicinol, is the central pharmacological feature that dictates both its sustained antileukemic effect and its challenging clinical management.

The use of Idarubicin is a calculated therapeutic risk, one that is justified in the context of aggressive hematologic malignancies like AML where the alternative is a rapidly fatal disease course. Its successful application is entirely dependent on a rigorous framework of meticulous clinical management. This framework includes careful patient selection, proactive surveillance of cardiac and hematologic function, precise dose adjustments for organ dysfunction, and the provision of aggressive supportive care within specialized facilities capable of managing the profound complications of therapy.

The role of Idarubicin in the treatment of AML continues to evolve. Initially established as the clear successor to standard-dose daunorubicin based on superior remission rates, its position has been re-evaluated in the modern era of dose-intensified and molecularly-guided therapy. The demonstration of equivalence with high-dose daunorubicin in the general AML population, and the subsequent discovery that high-dose daunorubicin may be superior in the high-risk, FLT3-ITD-positive subpopulation, marks a significant shift away from a "one-size-fits-all" approach. The future of AML induction therapy will increasingly involve selecting the optimal anthracycline backbone and dose not based on broad population averages, but on the specific genetic and molecular vulnerabilities of each patient's disease. In this new landscape, Idarubicin remains a powerful and essential component of the oncologist's armamentarium, but its application is becoming progressively more refined, targeted, and personalized.

Works cited

1. Idarubicin | C26H27NO9 | CID 42890 - PubChem, accessed July 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Idarubicin
2. Idarubicin - Wikipedia, accessed July 25, 2025, https://en.wikipedia.org/wiki/Idarubicin
3. idarubicin | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed July 25, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7083
4. Idarubicin | 58957-92-9 - ChemicalBook, accessed July 25, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5283235.htm
5. IDArubicin - Cancer Care Ontario | Cancer Care Ontario, accessed July 25, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43861
6. Idarubicin | CAS 58957-92-9 | SCBT - Santa Cruz Biotechnology, accessed July 25, 2025, https://www.scbt.com/p/idarubicin-58957-92-9
7. Definition of idarubicin hydrochloride - NCI Drug Dictionary, accessed July 25, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/idarubicin-hydrochloride
8. Idarubicin - brand name list from Drugs.com, accessed July 25, 2025, https://www.drugs.com/ingredient/idarubicin.html
9. Idarubicin Free Base | CAS# 58957-92-9 (free base) | anthracycline antineoplastic | MedKoo, accessed July 25, 2025, https://www.medkoo.com/products/44701
10. Idamycin PFS (Idarubicin Hydrochloride Injection): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 25, 2025, https://www.rxlist.com/idamycin-pfs-drug.htm
11. DRUG NAME: Idarubicin - BC Cancer, accessed July 25, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Idarubicin_monograph.pdf
12. PLASMA PHARMACOKINETICS OF IDARUBICIN AND ITS 13-HYDROXYMETABOLITE AFTER INTRAVENOUS AND ORAL ADMINISTRATION UNDER FASTING AND N, accessed July 25, 2025, https://medicaljournalssweden.se/actaoncologica/article/download/32846/37750/86974
13. go.drugbank.com, accessed July 25, 2025, https://go.drugbank.com/drugs/DB01177#:~:text=Idarubicin%20has%20antimitotic%20and%20cytotoxic,religation%20portion%20of%20the%20ligation%2D
14. Idarubicin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/drugs/DB01177
15. Idamycin PFS® idarubicin hydrochloride ... - accessdata.fda.gov, accessed July 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/050734s027lbl.pdf
16. Idarubicin Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 25, 2025, https://www.drugs.com/dosage/idarubicin.html
17. Plasma Pharmacokinetics of Idarubicin and its 13-Hydroxymetabolite after Intravenous and Oral Administration under Fasting and N, accessed July 25, 2025, https://www.tandfonline.com/doi/pdf/10.3109/02841869009096390
18. Idarubicin Hydrochloride Injection - ZAVEDOS - Pfizer, accessed July 25, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=15039
19. Idamycin PFS (idarubicin) for AML: Side Effects, Warnings - MedicineNet, accessed July 25, 2025, https://www.medicinenet.com/idamycin_pfs_injection_idarubicin_hydrochloride/article.htm
20. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed July 25, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=29388
21. (PDF) Idarubicin versus Doxorubicin in Acute Myeloid Leukemia: A ..., accessed July 25, 2025, https://www.researchgate.net/publication/377359178_Idarubicin_versus_Doxorubicin_in_Acute_Myeloid_Leukemia_A_Parallel_Randomized_Trial_with_Pharmacoeconomic_Analysis
22. Idarubicin versus Doxorubicin in Acute Myeloid Leukemia: A Parallel Randomized Trial with Pharmacoeconomic Analysis - Pharmaceutical Sciences, accessed July 25, 2025, https://ps.tbzmed.ac.ir/Inpress/ps-39960.pdf
23. MPN Recruiting Phase 2 Trials for Idarubicin (DB01177) | DrugBank Online, accessed July 25, 2025, https://go.drugbank.com/indications/DBCOND0076875/clinical_trials/DB01177?phase=2&status=recruiting
24. The efficacy and safety of daunorubicin versus idarubicin combined ..., accessed July 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7302600/
25. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. - ASCO Publications, accessed July 25, 2025, https://ascopubs.org/doi/10.1200/JCO.1992.10.7.1103
26. (idarubicin) dosing, indications, interactions, adverse effects, and more, accessed July 25, 2025, https://reference.medscape.com/drug/idarubicin-342123
27. Idarubicin: Drug information - Uptodate Online Free, accessed July 25, 2025, https://www.uptodateonline.ir/contents/UTD.htm?39/43/40630?source=see_link
28. Idarubicin: MedlinePlus Drug Information, accessed July 25, 2025, https://medlineplus.gov/druginfo/meds/a691004.html
29. Idarubicin Uses, Side Effects & Warnings - Drugs.com, accessed July 25, 2025, https://www.drugs.com/mtm/idarubicin.html
30. PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrIDARUBICIN idarubicin hydrochloride injection Preservative Free Sol, accessed July 25, 2025, https://webfiles.pfizer.com/file/9027d8e2-110c-4113-a261-45d46ba20a3d?referrer=ccb731e5-4f2d-4f4a-b2dc-e5e912145fc6
31. Idarubicin | Cancer Research UK, accessed July 25, 2025, https://www.cancerresearchuk.org/about-cancer/treatment/drugs/idarubicin
32. Idarubicin (Idamycin) - UPMC, accessed July 25, 2025, https://dam.upmc.com/-/media/cancercenter/for-patients/documents/chemo-pdfs/idarubicin.pdf?la=en&rev=463a339c155e41fd93cdd1b5f26ebd09&hash=60D1772DE3F7535B72DC52AC4A964F04
33. Idarubicin - Together by St. Jude™, accessed July 25, 2025, https://together.stjude.org/en-us/treatment-tests-procedures/medicines-list/idarubicin.html
34. Idarubicin (Idamycin®) | OncoLink, accessed July 25, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/idarubicin-idamycin-R
35. Idarubicin Interactions Checker - Drugs.com, accessed July 25, 2025, https://www.drugs.com/drug-interactions/idarubicin.html
36. go.drugbank.com, accessed July 25, 2025, https://go.drugbank.com/drugs/DB01177#:~:text=The%20metabolism%20of%20Idarubicin%20can%20be%20decreased%20when%20combined%20with%20Betaxolol.&text=Betrixaban-,The%20risk%20or%20severity%20of%20bleeding%20can%20be,Betrixaban%20is%20combined%20with%20Idarubicin.&text=Bevacizumab-,The%20risk%20or%20severity%20of%20cardiotoxicity%20can%20be,Bevacizumab%20is%20combined%20with%20Idarubicin.
37. Prospective Randomized Comparison of Idarubicin and High-Dose ..., accessed July 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2017.72.8618
38. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study - American Society of Hematology, accessed July 25, 2025, https://ashpublications.org/blood/article/117/8/2358/28389/Randomized-study-of-induction-therapy-comparing
39. Daunorubicin vs Doxorubicin Comparison - Drugs.com, accessed July 25, 2025, https://www.drugs.com/compare/daunorubicin-vs-doxorubicin
40. Generic Idamycin PFS Availability - Drugs.com, accessed July 25, 2025, https://www.drugs.com/availability/generic-idamycin-pfs.html
41. IDAMYCIN® | Pfizer, accessed July 25, 2025, https://www.pfizer.com/products/product-detail/idamycin
42. Pricing for 4 Idarubicin Brands - Medindia, accessed July 25, 2025, https://www.medindia.net/drug-price/idarubicin.htm